Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Immune Therapy’s Cancer Promise Creates Research Rush in Bloomberg
By Naomi Kresge and Robert Langreth May 29, 2014

Excerpt:
"A new class of medicines that help the body’s own immune cells fight tumors could target a wide set of cancers, opening a $35 billion market for Merck (MRK) & Co., Bristol-Myers Squibb Co., AstraZeneca Plc and Roche (ROG) Holding AG.

The drugmakers will use the world’s largest meeting of cancer doctors, the American Society of Clinical Oncology, to stake their claim on the new technology, which aims to interrupt cancer’s ability to switch off immune system cells that might otherwise attack it.

For years, the idea was only seen as usable against a handful of uncommon tumors. Now, new evidence the drugs may work in a wider range of malignancies, advanced in just the last two years, has spurred Merck, Bristol-Myers, AstraZeneca and Roche to begin at least 78 clinical trials. While the research, with more than 19,000 patients, could cost the four companies as much as $1.3 billion, the payoff would be the creation of a new market that Citigroup Inc. (C) analysts have predicted could reach $35 billion a year."

Article at:
http://www.bloomberg.com/news/2014-05-29/immune-therapy-s-cancer-promise-creates-research-rush.html